BioCardia, Inc. (BCDA) vs Estrella Immunopharma, Inc. (ESLA)
A side-by-side comparison of BioCardia, Inc. and Estrella Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BCDA
BioCardia, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
ESLA
Estrella Immunopharma, Inc.
$0.42HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT
Total return — BCDA vs ESLA
growth of $100 · dividends reinvested · last 5yBCDA -99.2% (-61.8%/yr)ESLA -95.5% (-46.2%/yr)ESLA compounded faster over this window
Log scale — wide-divergence pair
BCDA ESLA
BCDA vs ESLA: by the numbers
- •ESLA is the larger company ($18M vs $16M market cap).
Metrics side by side
Valuation
| Metric | BCDA | ESLA |
|---|---|---|
| P/B ratio | 5.87 | N/A |
Profitability
| Metric | BCDA | ESLA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -271.81% | N/A |
| ROIC | -273.70% | N/A |
Growth (annualized)
| Metric | BCDA | ESLA |
|---|---|---|
| Total return CAGR (5Y) | -61.39% | -46.34% |
Frequently asked
- How have BCDA and ESLA total returns compared?
- Over the past 5 years, BCDA delivered -61.39% and ESLA delivered -46.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.